轉移性攝護腺癌患者在系統性治療中接受不同新冠疫苗接種之反應

楊立宇、李建儀、裘坤元、陳正哲

台中榮民總醫院 外科部 泌尿科

The Side Effects of Different Vaccinations for Metastatic Prostate Cancer Patients under Systemic Treatment

Li-Yu Yang, Jian-Ri Li, Kun-Yuan Chiu, Cheng-Che Chen

Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taiwan

Purpose: In March 2020, Coronavirus disease (COVID-19) pandemic developed. In Taiwan, vaccination started since March 2021 with different available options. Clinical trials reported various but mild side effects with different vaccines. Prostate cancer is the fifth leading cause of cancer-related deaths in Taiwan. In the advanced stage, these patients may need to receive systemic therapies, such as hormone therapy, chemotherapy, target therapy, Ra-223, or immunotherapy. We focused on the side effects of these patient groups when receiving vaccination.

Materials and Methods: We prospectively investigate the patients, who receiving systemic therapies for advanced prostate cancer since March 2021. Inclusion criteria were age 50 or older with the informed consent, and having received one or more COVID-19 vaccines. Exclusion criteria

were as below: Patients with immunosuppressive diseases or drugs not related to prostate cancer treatment, weight less than 40 kg, and recent COVID-19 infection. We contact the vaccinated patients and recorded any side effects they experienced.

Results: One hundred participants were enrolled in the study, and 98% of them continued their original cancer treatment despite receiving COVID-19 vaccination. Among the participants, 96% continued hormone therapy, while 32% received enzalutamide or apalutamide, 9% received abiraterone, and 4% received radiation therapy. Regarding vaccine type, 37 participants received AstraZeneca vaccine, 57 received Moderna vaccine, 2 received MVC vaccine, 11 received Pfizer-BioNTech, and 7 received Johnson & Johnson/Janssen’s vaccine . Of all participants, 55% reported no symptoms following vaccination, while 25% experienced injection site pain and 5% reported fever. 28 participants received only AstraZeneca vaccine, with 40.5% reporting no symptoms, 13.5% experiencing injection site pain, and 8.1% reporting fever or fatigue. 5.4% reported injection site redness and swelling. 50 participants received only Moderna, with 49.1% reporting no symptoms, 8.8% experiencing injection site pain, 7% reporting muscle soreness, 3.5% reporting injection site redness and swelling, and 1.8% reporting fatigue.

Conclusion: The majority of participants did not experience significant adverse events after receiving the COVID-19 vaccine and were able to continue their original treatment without interruption.